거래소, 삼성바이오 ‘상장 유지’ 결정…내일부터 거래 재개

The operator of Korea's stock markets has decided to allow traders to resume buying and selling shares of Samsung Biologics.
The company is accused of intentionally breaking accounting rules to inflate its profits.
But the Exchange said Monday, after a meeting of its Corporate Review Committee,... that in the interest of maintaining the company's continuity and transparency -- and to protect investors -- trading will resume on Tuesday.
The company was suspended a month ago after the findings by the Financial Services Commission.